[To learn English]
Novo Nordisk plans to seek Chinese regulatory approval for its Wegovy weight-loss pill ‘very soon,’ its CEO said on Tuesday, as it moves to catch up with rival Eli Lilly in the world’s second-largest pharmaceutical market.
Denmark’s Novo and U.S.-based Lilly believe weight-loss pills could attract patients reluctant to use injections and are racing to expand use of drugs that have transformed obesity treatment and reshaped the global pharmaceutical industry.
诺和诺德计划“很快”在中国提交其减肥药Wegovy的监管审批申请，该公司CEO周二表示，此举旨在追赶竞争对手礼来，争夺全球第二大医药市场。
丹麦的诺和诺德和美国的礼来都相信，口服减肥药能吸引不愿使用注射剂的患者，两家公司正竞相扩大这类药物的应用范围——这些药物已彻底改变了肥胖症治疗，并重塑了全球制药行业。
LearnEnglish Leave a remark